|
FY2026
12 months to Jun 30, 2026
|
FY2025
12 months to Jun 30, 2025
|
FY2024
12 months to Jun 30, 2024
|
FY2023
12 months to Jun 30, 2023
|
FY2022
12 months to Jun 30, 2022
|
|
|---|---|---|---|---|---|
| Product sales, net | |||||
| Royalty revenue | |||||
| Total revenues | |||||
| Cost of revenues (including amortization of currently marketed intangible assets, 2026: $6,126: 2025: $3,937, 2024: $Nil) | |||||
| Research & development | |||||
| Manufacturing commercialization | |||||
| Management and administration | |||||
| Selling, general and administration | |||||
| Fair value remeasurement of contingent consideration | |||||
| Fair value remeasurement of warrant liability | |||||
| Other operating income and expenses | |||||
| Finance costs | |||||
| Loss before income tax | |||||
| Income tax (expense)/benefit | |||||
| Loss attributable to the owners of Mesoblast Limited | |||||
| Losses per share from continuing operations attributable to the ordinary equity holders of the Group: | |||||
| Basic - losses per share (in USD per share) | |||||
| Diluted - losses per share (in USD per share) |
Loading...
